Diamyd Medical AB (publ) and JDRF have entered into a fouour-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd. The grant will be funded under JDRF's Industry Discovery & Development Partnerships program that focuses on commercialization of therapeutics and devices for the treatment, cure, and prevention of type 1 diabetes and its complications.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.8 SEK | +0.44% | -4.03% | +110.05% |
May. 16 | Diamyd Medical AB Updates on the Registrational Phase 3 Trial | CI |
Apr. 18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+110.05% | 131M | |
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- DMYD B Stock
- News Diamyd Medical AB
- Diamyd Medical AB Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes